

PEPSICO

PepsiCo Financial Analysis

Kaleab Alemayehu, Devin Cager, Franky Jiang, Brandon Sanchez, Jing Wang,

Kevin Xu, and Yan Zeng

ECON 118: Financial Accounting Analysis and Planning

Professor Scott Fulkerson

UCSB

Significant Assets

Pepsi is constantly expanding its network of property and improving their manufacturing equipment

- Their most significant asset on their balance sheet is Property Plant and Equipment

2019: PPE was \$19,305 million 2020: PPE was \$21,369 million

Side Note: Coca Cola's PPE was

\$10,777 million in 2020





Significant Assets - Relation to Business Strategy

Pepsi has a heavy emphasis on cost efficiency within their business strategy

Meaning, they primarily focus on manufacturing and distribution efficiency in order to gain a competitive edge over their competitors

- Relates to their most significant asset, PPE, because acquiring manufacturing businesses allows them to expand their warehouses and property worldwide, delivering their snacks and beverages seamlessly throughout the globe.





Our brands

- -Frito-Lay
- -Gatorade
- -Pepsi-Cola
- -Quaker
- -Tropicana



Our Distribution Network

- -Direct-Store-Delivery
- -Customer Warehouse
- -Distributor Networks
- -E-commerce
- -Ingredients and Other Supplies



Risk factors concerning PepsiCo

- Reduction in future demand
 - PepsiCo must respond to consumer trends and preferences
 - Consumer perceptions of Pepsi products being unhealthy would negatively impact sales
 - Higher demand for healthier alternatives can have adverse effects on sales
- How has PepsiCo addressed this issue?
 - Invested in data analytics to better understand consumer preferences
 - Offering alternatives such as Bubly and diet drinks



Risk factors cont.

- Limitations on the marketing or sale of products
 - Governments are concerned about public health, as diet-related diseases are on the rise
 - Possible limitations include taxing sugary beverages, color labeling ingredients, and limiting the sale in certain locations
- How has PepsiCO addressed this issue
 - Lobbying?
 - Adapt different business strategies in certain locations



Evolution & Growth

- Acquiring and Combinations
 - Consistently merges with different manufacturers to acquire a larger inventory or products and to become a greater presence globally
 - Invests billions into advertising and marketing so that their products are viewed by consumers
 - Forms partnerships with other industries like the sports industry to relate to consumers





Evolution & Growth

Going Forward

- Has recently launched sustainability agenda designed to meet changing consumer and societal needs
- In the future they may begin acquiring and combining with healthier and environmentally conscious manufacturers and companies to further diversify their products and push for a healthier world





6) Financial Statement Foresight

- Net receivables increased from $7,822 \rightarrow 8,404$
- Land increased from $1,130 \rightarrow 1,171$
- Buildings and improvements increased from $9,314 \rightarrow 10,214$
- Cash and cash equivalents increased from $5,509 \rightarrow 8,185$
- Dividends payable increased from $1,351 \rightarrow 1430$.
- Pepsi has a negative cash conversion cycle
- Pepsico's acquisition of Rockstar Energy Drinks



Financial Statement Foresight cont.

- We can see that their payables and are increasing at a rate similar to that of their receivables which may possibly point to some stagnation in the business cycle.
 - Could be due to factors such as their long-term debt consolidation plans surrounding land acquisitions and building improvements.


- Another point of concern could be Pepsico's ability to continue to generate revenue proportional to their advertising expenditures.
 - PepsiCo spent nearly 1.7B on ad spend alone in 2019.

Potential Manipulation


• Early revenue recognition

• provisions for income tax, it seems like it could be one of the main factors to use to control net income.

PEP Revenue Growth Rate



U.S. market growth across staple categories



Source: J.P. Morgan Research estimates

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021


Weekly / August 27, 2021 / 70(34);1167-1169

On August 24, 2021, this report was posted online as an MMWR Early Release.

Ashley Fowlkes, ScD¹; Manjusha Gaglani, MBBS²; Kimberly Groover, PhD³; Matthew S. Thiese, PhD⁴; Harmony Tyner, MD⁵; Katherine Ellingson, PhD⁶; HEROES-RECOVER Cohorts (<u>View author affiliations</u>)

View suggested citation

During December 14, 2020–April 10, 2021, data from the HEROES-RECOVER Cohorts,* a network of prospective cohorts among frontline workers, showed that the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines were approximately 90% effective in preventing symptomatic and asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19, in real-world conditions (*1,2*). This report updates vaccine effectiveness (VE) estimates including all COVID-19 vaccines available through August 14, 2021, and examines whether VE differs for adults with increasing time since completion of all recommended vaccine doses. VE before and during SARS-CoV-2 B.1.617.2 (Delta) variant predominance, which coincided with an increase in reported COVID-19 vaccine breakthrough infections, were compared (*3,4*).



	Forecast										Continuing Terminal	
Year	Growth	2019	Growth	2020	Growth	2021	Growth	2022	Growth	2023	Growth	2024
Net Revenue	3.00%	66600.83	10.00%	73260.91	8.00%	79121.786	2.00%	80704.22	1.50%	81914.79	1.00%	82733.93294
Cost of Sales		29977.43	2.03%	30585.98	2.03%	31206.872	2.03%	31840.37	2.03%	32486.73	2.03%	33146.21119
Gross Profit	3.81%	36623.40	16.52%	42674.94	12.28%	47914.915	1.98%	48863.85	1.15%	49428.05	0.32%	49587.72175
SG&A	5.00%	26428.50	10.00%	29071.35	10.00%	31978.485	5.00%	33577.41	5.00%	35256.28	3%	36313.9681
Operating Profit(EBIT)	0.84%	10194.90	33.44%	13603.59	17.15%	15936.430	-4.08%	15286.44	-7.29%	14171.77	-6.34%	13273.75365
Pension/Retiree Medical benefits	20.00%	357.60	-30.00%	250.32	150.00%	625.800	20.00%	750.96	15.00%	863.60	-20%	690.8832
Interest Expense		1220.00	10.00%	1342.00	10.00%	1476.200	3.00%	1520.49	-20.00%	1216.39	-10%	1094.74992
Provision for Income Tax	-150.00%	1685.00	20.00%	2022.00	20.00%	2426.400	5.00%	2547.72	3.00%	2624.15	-50%	1312.0758
Non-Controlling interest	-10.00%	39.60	-15.00%	33.66	-10.00%	30.294	-100.00%	0.00	N/A	0.00	N/A	0
Net income	-45.12%	6892.70	44.44%	9955.61	14.28%	11377.736	-8.00%	10467.28	-9.55%	9467.63	7.48%	10176.04473
Depreciation and amortization	1%	2422.99	2%	2471.4498	2%	2520.878796	2%	2571.296372	2%	2622.722299	2%	2675.176745
Share-based compensation expense		281.6	30%	366.08	20%	439.296	-30%	307.5072	-20%	246.00576	-10%	221.405184
Restructuring and impairment charges		400.4	20%	480.48	20%	576.576	-30%	403.6032	-20%	322.88256	40%	452.035584
Cash payment for restructuring charges		-280.5	20%	-336.6	20%	-403.92	-30%	-282.744	-20%	-226.1952	-20%	-180.95616
Charge related to the transaction with Tingvi	N/A	0	N/A	0	N/A	0	N/A	0	N/A	0	N/A	0
Pension and retiree medical plan expenses	300%	884	-40%	530.4	-40%	318.24	30%	413.712	30%	537.8256	-10%	484.04304
Pension and retiree medical plan contributions	-50%	-854	10%	-939.4	20%	-1127.28	30%	-1465.464	-10%	-1318.9176	-15%	-1121.07996
Deferred income taxes and other tax charge and credits	-200%	531	20%	637.2	-300%	-1274.4	30%	-1656.72	-5%	-1573.884	-20%	-1259.1072
Other net tax benefits related to international reorganiza	N/A	0	N/A	0	N/A	0	N/A	0	N/A	0	N/A	0
Net tax(benefit)/expense related to the TCJ Act	N/A	0	N/A	0	N/A	0	N/A	0	N/A	0	N/A	0
Change in assets and liabilities:												
Accounts and notes receivable	10%	-278.3	50%	-417.45	40%	-584.43	-40%	-350.658	-30%	-245.4606	-40%	-147.27636
Inventories	5%	-182.7	80%	-328.86	50%	-493.29	-60%	-197.316	-20%	-157.8528	-30%	-110.49696
Prepaid expenses and other current assets	500%	54	300%	216	50%	324	-20%	259.2	-30%	181.44	-20%	145.152
Accounts payable other current liabilities	-50%	441	100%	882	50%	1323	-30%	926.1	-30%	648.27	30%	842.751
Income tax payable	-150%	-166.5	-250%	249.75	50%	374.625	-10%	337.1625	-10%	303.44625	20%	364.1355
Other, net	-10%	-230.4	-10%	-207.36	-5%	-196.992	10%	-216.6912	10%	-238.36032	10%	-262.196352
Net Cash Provided by Operating Activities	5.31%	9915.2857	36.75%	13559.2966	-2.84%	13174.0393	-12.58%	11516.2636	-8.22%	10569.5524	16.18%	12279.6308
Capital spending	10%	-3610.2	15%	-4151.73	20%	-4982.076	10%	-5480.2836	-15%	-4658.24106	-25%	-3493.680795
Sales of property, plant and equipment	15%	154.1	15%	177.215	50%	265.8225	-50%	132.91125	-30%	93.037875	30%	120.9492375
Free Cash flow for common Equity, non-GAAP measure	3.07%	6459.1857	48.39%	9584.7816	-11.76%	8457.7858	-27.06%	6168.8912	-2.67%	6004.3492	48.34%	8906.8992
Taxed Cash Flow (21%)		5102.756703		7571.977451		6681.650784		4873.424054		4743.435853		7036.450392
Present Value Factor		0.93		0.87		0.80		0.74		0.67		
Present Value Free Cach Flows		4,770		6,585		5,375		3,603		3,197		

	Forecast										Continui	ing Terminal
Year	Growth	2019	Growth	2020	Growth	2021	Growth	2022	Growth	2023	Growth	2024
Net Revenue	3.00%	66600.83	10.00%	73260.91	8.00%	79121.786	2.00%	80704.22	1.50%	81914.79	1.00%	82733.93294
Cost of Sales		29977.43	2.03%	30585.98	2.03%	31206.872	2.03%	31840.37	2.03%	32486.73	2.03%	33146.21119
Gross Profit	3.81%	36623.40	16.52%	42674.94	12.28%	47914.915	1.98%	48863.85	1.15%	49428.05	0.32%	49587.72175
SG&A	5.00%	26428.50	10.00%	29071.35	10.00%	31978.485	5.00%	33577.41	5.00%	35256.28	3%	36313.9681
Operating Profit(EBIT)		10194.90	33.44%	13603.59	17.15%	15936.430	-4.08%	15286.44	-7.29%	14171.77	-6.34%	13273.75365
Pension/Retiree Medical benefits	20.00%	357.60	-30.00%	250.32	150.00%	625.800	20.00%	750.96	15.00%	863.60	-20%	690.8832
Interest Expense	-20.00%	1220.00	10.00%	1342.00	10.00%	1476.200	3.00%	1520.49	-20.00%	1216.39	-10%	1094.74992
Provision for Income Tax	-150.00%	1685.00	20.00%	2022.00	20.00%	2426.400	5.00%	2547.72	3.00%	2624.15	-50%	1312.0758
Non-Controlling interest	-10.00%	39.60	-15.00%	33.66	-10.00%	30.294	-100.00%	0.00	N/A	0.00	N/A	0
Net income	-45.12%	6892.70	44.44%	9955.61	14.28%	11377.736	-8.00%	10467.28	-9.55%	9467.63	7.48%	10176.04473
Depreciation and amortization		2422.99	2%	2471.4498	2%	2520.878796	2%	2571.296372	2%	2622.722299	2%	2675.176745
Share-based compensation expense		281.6	30%	366.08	20%	439.296	-30%	307.5072	-20%	246.00576	-10%	221.405184
Restructuring and impairment charges		400.4	20%	480.48	20%	576.576	-30%	403.6032	-20%	322.88256	40%	452.035584
Cash payment for restructuring charges		-280.5	20%	-336.6	20%	-403.92	-30%	-282.744	-20%	-226.1952	-20%	-180.95616
Charge related to the transaction with Tingvi	N/A	0	N/A	0	N/A	0	N/A	0	N/A	0	N/A	0
Pension and retiree medical plan expenses	300%	884	-40%	530.4	-40%	318.24	30%	413.712	30%	537.8256	-10%	484.04304
Pension and retiree medical plan contributions	-50%	-854	10%	-939.4	20%	-1127.28	30%	-1465.464	-10%	-1318.9176	-15%	-1121.07996
Deferred income taxes and other tax charge and credits	-200%	531	20%	637.2	-300%	-1274.4	30%	-1656.72	-5%	-1573.884	-20%	-1259.1072
Other net tax benefits related to international reorganiza	N/A	0	N/A	0	N/A	0	N/A	0	N/A	0	N/A	0
Net tax(benefit)/expense related to the TCJ Act	N/A	0	N/A	0	N/A	0	N/A	0	N/A	0	N/A	0
Change in assets and liabilities:												
Accounts and notes receivable	10%	-278.3	50%	-417.45	40%	-584.43	-40%	-350.658	-30%	-245.4606	-40%	-147.27636
Inventories	5%	-182.7	80%	-328.86	50%	-493.29	-60%	-197.316	-20%	-157.8528	-30%	-110.49696
Prepaid expenses and other current assets	500%	54	300%	216	50%	324	-20%	259.2	-30%	181.44	-20%	145.152
Accounts payable other current liabilities	-50%	441	100%	882	50%	1323	-30%	926.1	-30%	648.27	30%	842.751
Income tax payable	-150%	-166.5	-250%	249.75	50%	374.625	-10%	337.1625	-10%	303.44625	20%	364.1355
Other, net	-10%	-230.4	-10%	-207.36	-5%	-196.992	10%	-216.6912	10%	-238.36032	10%	-262.196352
Net Cash Provided by Operating Activities	5.31%	9915.2857	36.75%	13559.2966	-2.84%	13174.0393	-12.58%	11516.2636	-8.22%	10569.5524	16.18%	12279.6308
Capital spending	10%	-3610.2	15%	-4151.73	20%	-4982.076	10%	-5480.2836	-15%	-4658.24106	-25%	-3493.680795
Sales of property, plant and equipment	15%	154.1	15%	177.215	50%	265.8225	-50%	132.91125	-30%	93.037875	30%	120.9492375
Free Cash flow for common Equity. non-GAAP measu	3.07%	6459.1857	48.39%	9584.7816	-11.76%	8457.7858	-27.06%	6168.8912	-2.67%	6004.3492	48.34%	8906.8992
Taxed Cash Flow (21%)		5102.756703		7571.977451		6681.650784		4873.424054		4743.435853		7036.450392
Present Value Factor		0.93		0.87		0.80		0.74		0.67		
Present Value Free Cash Flows		4,770		6,585		5,375		3,603		3,197		

CAPM

=

Risk Free Rate of Return

+

Beta

X

(Market Risk Premium-Risk Free Rate of Return)

Beta=Covariance/Variance


Risk Free Rate of Return=5 Year Treasury Bond Rate

Market risk Premium= Expected Market Return-Risk Free Rate of Return

Expected Market Return= Average YOY growth in S&P

Tre	asury Rate as 20	18	2.75					
Risk Free Rate of Returns 2018		2.75						
	Beta		1.02					
М	Market Risk Premium		6.45	Exp	ected Market Ret	ed Market Return		
	CAPM		6.519557307					
	Growth		4%	according to their CEO guidance.				
Shar	e outstanding as	2018	1415					
	Diluted		1425					
(urrent share pric	е	\$156.39					
Year	2013	2014	2015	2016	2017	2018		
PEP Stock Price	100	117	128	137	162	154		
S&P	100	114	115	129	157	150		
Covariance	504							
Variance	494.7							


PEP Stock Chart



Source : Yahoo Finance

Sum of Present Value Free Cash Flow	23,529						
Present Value of Continuing Value	188203.3061	=	<u>Continu</u>	uing Value(1	Х	0.67	
			CAPM (6.				
Total	211,733						
Adjusted Midyear Discount	1.032597787						
Total Present Value FCF to Equity	218634.5677						
Share outstanding as 2018	1415						
Estimated Value Per Share	154.5120619						
Current Share Price	\$157.09						
Percent Difference	-1.64%						

PEP Stock Chart



Source : Yahoo Finance

Thanks For Watching! Have A Wonderful Day And Stay Safe!